[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组, 李兰娟, 等.肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志,2019,35(1):38-44.
[2] 谭文婷, 邓国宏.肝衰竭前期的发病机制进展[J].中华肝脏病杂志,2020,28(4):302-307.
[3] Peng J, Li J, Huang J, et al. p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization[J]. Theranostics,2019,9(26):8344-8361.
[4] Papachristoforou E, Ramachandran P. Macrophages as key regulators of liver health and disease[J]. Int Rev Cell Mol Biol,2022,368:143-212.
[5] Liu Y, Xu R, Gu H, et al. Metabolic reprogramming in macrophage responses[J]. Biomark Res,2021,9(1):1.
[6] 王晓晶, 张小平, 宁琴.肝衰竭的免疫发病机制[J].临床肝胆病杂志,2014,30(10):984-991.
[7] Antoniades C G, Quaglia A, Taams L S, et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans[J]. Hepatology,2012,56(2):735-746.
[8] 田璎, 吴杰, 邹畅.Warburg效应在肿瘤耐药中的研究进展[J].中国现代医生,2024,62(16):762-766.
[9] 姜晓旭, 郑义鹏, 赵九洲, 等.M1型巨噬细胞糖代谢重编程机制及其在炎症启动中的关键作用[J].癌变·畸变·突变,2019,31(1):79-81.
[10] Iovino M, Colonval M, Wilkin C, et al. Novel XBP1s-independent function of IRE1 RNase in HIF-1α-mediated glycolysis upregulation in human macrophages upon stimulation with LPS or saturated fatty acid[J]. Front Immunol,2023,14:1204126.
[11] Groeger M, Matsuo K, Arash E H, et al. Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages[J]. Nat Commun,2023,14(1):3902.
[12] Li J, Wang T, Xia J, et al. Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases[J]. FASEB J,2019,33(11):11640-11654.
[13] Pajak B, Siwiak E, Soltyka M, et al. 2-deoxy-D-glucose and its analogs: from diagnostic to therapeutic agents[J]. Int J Mol Sci,2020,21(1):234.
[14] 蓝春花, 陈成英, 蓝利, 等.2-DG抑制糖酵解和线粒体自噬调控M1型巨噬细胞极化[J].广西医科大学学报,2021,38(4):704-709.
[15] Xu F, Guo M, Huang W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH[J]. Redox Biol,2020,36:101634.
[16] Jang S E, Hyam S R, Han M J, et al. Lactobacillus brevis G-101 ameliorates colitis in mice by inhibiting NF-κB, MAPK and AKT pathways and by polarizing M1 macrophages to M2-like macrophages[J]. J Appl Microbiol,2013,115(3):888-896.
[17] Yang Y, Sheng J, Sheng Y, et al. Lapachol treats non-alcoholic fatty liver disease by modulating the M1 polarization of Kupffer cells via PKM2[J]. Int Immunopharmacol,2023,120:110380.
[18] Fan N, Zhang X, Zhao W, et al. Covalent inhibition of pyruvate kinase M2 reprograms metabolic and inflammatory pathways in hepatic macrophages against non-alcoholic fatty liver disease[J]. Int J Biol Sci,2022,18(14):5260-5275.
[19] Wan L, Xia T, Du Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells[J]. FASEB J,2019,33(7):8530-8542.
[20] Zhao H, Lu J, He F, et al. Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway via IRS2-proteasome degradation[J]. Front Immunol,2022,13:931087.
[21] Freemerman A J, Johnson A R, Sacks G N, et al. Metabolic reprogramming of macrophages glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype[J]. J Biol Chem,2014,289(11):7884-7896.
[22] Boeing T, de Souza P, Speca S, et al. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties[J]. Br J Pharmacol,2020,177(10):2393-2408.
[23] Fasoulakis Z, Koutras A, Syllaios A, et al. Breast cancer apoptosis and the therapeutic role of luteolin[J]. Chirurgia (Bucur),2021,116(2):170-177.
[24] Shao C, Lin S, Liu S, et al. HIF1α-Induced glycolysis in macrophage is essential for the protective effect of ouabain during endotoxemia[J]. Oxid Med Cell Longev,2019,2019:7136585.
[25] del Rey M J, Valin A, Usategui A, et al. HIF-1α knockdown reduces glycolytic metabolism and induces cell death of human synovial fibroblasts under normoxic conditions[J]. Sci Rep,2017,7:3644.
[26] 张步春, 张甜甜, 项楚涵, 等.木犀草素通过HIF-1α抑制糖酵解调控M1型巨噬细胞极化[J].中国药理学通报,2023,39(2):244-251.
[27] 蓝春花, 孟玲, 陈成英, 等.绿原酸抑制糖酵解及脂肪酸代谢调控M1型巨噬细胞极化[J].中国免疫学杂志,2021,37(20):2440-2444.
[28] Russo S, Kwiatkowski M, Govorukhina N, et al. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites[J]. Front Immunol,2021,12:746151.
[29] Xu J, Tian Z, Li Z, et al. Puerarin-Tanshinone ⅡA suppresses atherosclerosis inflammatory plaque via targeting succinate/HIF-1α/IL-1β axis[J]. J Ethnopharmacol,2023,317:116675.
[30] Infantino V, Convertini P, Cucci L, et al. The mitochondrial citrate carrier: a new player in inflammation[J]. Biochem J,2011,438(3):433-436.
[31] el Kasmi K C, Stenmark K R. Contribution of metabolic reprogramming to macrophage plasticity and function[J]. Semin Immunol,2015,27(4):267-275. |
